Loading…
Xcel Research LLC was cited for manufacturing and selling unapproved new drugs including Retatrutide, Cagrilintide, Semaglutide, Mazdutide, Survodutide, and Sermorelin through their website in violation of sections 505(a) and 301(d) of the FD&C Act. Despite labeling claims that products were "for research use only" and "not intended for human use," the FDA found evidence on the company's website establishing these products were intended for human use, with marketing claims describing weight management, insulin sensitivity improvements, and cardiovascular protection benefits. The violations were identified during an FDA website review conducted in October 2024.